Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activities
Growth Metrics
Income Statement
Others
Ratios

Acro Biomedical (ACBM) Cash from Financing Activities (2017 - 2025)

Acro Biomedical (ACBM) has 9 years of Cash from Financing Activities data on record, last reported at $25152.0 in Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 144.43% year-over-year to $25152.0; the TTM value through Dec 2025 reached $199924.0, up 443.39%, while the annual FY2025 figure was $199924.0, 443.39% up from the prior year.
  • Cash from Financing Activities reached $25152.0 in Q4 2025 per ACBM's latest filing, down from $58707.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $93759.0 in Q2 2025 and bottomed at -$241635.0 in Q2 2021.
  • Average Cash from Financing Activities over 5 years is $4128.0, with a median of $6607.0 recorded in 2024.
  • Peak YoY movement for Cash from Financing Activities: crashed 492.42% in 2021, then soared 36811.11% in 2024.
  • A 5-year view of Cash from Financing Activities shows it stood at $1091.0 in 2021, then crashed by 78.74% to $232.0 in 2022, then skyrocketed by 4088.79% to $9718.0 in 2023, then increased by 5.89% to $10290.0 in 2024, then skyrocketed by 144.43% to $25152.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were $25152.0 in Q4 2025, $58707.0 in Q3 2025, and $93759.0 in Q2 2025.